1
|
Ji H, Wang J, Lu B, Li J, Zhou J, Wang L, Xu S, Peng P, Hu X, Wang K. SP1 induced long non-coding RNA AGAP2-AS1 promotes cholangiocarcinoma proliferation via silencing of CDKN1A. Mol Med 2021; 27:10. [PMID: 33522895 PMCID: PMC7852216 DOI: 10.1186/s10020-020-00222-x] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/08/2020] [Accepted: 09/29/2020] [Indexed: 12/11/2022] Open
Abstract
BACKGROUND LncRNA can regulate gene at various levels such as apparent genetics, alternative splicing, and regulation of mRNA degradation. However, the molecular mechanism of LncRNA in cholangiocarcinoma is still unclear. This deserves further exploration. METHODS We investigated the expression of AGAP2-AS1 in 32 CCA tissues and two CCA cell lines. We found a LncRNA AGAP2-AS1 which induced by SP1 has not been reported in CCA, and Knockdown and overexpression were used to investigate the biological role of AGAP2-AS1 in vitro. CHIP and RIP were performed to verify the putative targets of AGAP2-AS1. RESULTS AGAP2-AS1 was significantly upregulated in CCA tumor tissues. SP1 induced AGAP2-AS1 plays an important role in tumorigenesis. AGAP2-AS1 knockdown significantly inhibited proliferation and caused apoptosis in CCA cells. In addition, we demonstrated that AGAP2-AS1 promotes the proliferation of CCA. CONCLUSIONS We conclude that the long non-coding RNA AGAP2-AS1 plays a role in promoting the proliferation of cholangiocarcinoma.
Collapse
Affiliation(s)
- Hao Ji
- Department of Oncology, Second Affiliated Hospital, Nanjing Medical University, Nanjing, 210000 Jiangsu People’s Republic of China
- The Second Clinical Medical College of Nanjing Medical University, Nanjing, China
| | - Juan Wang
- Department of Oncology, Second Affiliated Hospital, Nanjing Medical University, Nanjing, 210000 Jiangsu People’s Republic of China
- The Second Clinical Medical College of Nanjing Medical University, Nanjing, China
| | - Binbin Lu
- Department of Oncology, Second Affiliated Hospital, Nanjing Medical University, Nanjing, 210000 Jiangsu People’s Republic of China
- The Second Clinical Medical College of Nanjing Medical University, Nanjing, China
| | - Juan Li
- Department of Oncology, Second Affiliated Hospital, Nanjing Medical University, Nanjing, 210000 Jiangsu People’s Republic of China
- The Second Clinical Medical College of Nanjing Medical University, Nanjing, China
| | - Jing Zhou
- Department of Oncology, Second Affiliated Hospital, Nanjing Medical University, Nanjing, 210000 Jiangsu People’s Republic of China
- The Second Clinical Medical College of Nanjing Medical University, Nanjing, China
| | - Li Wang
- Department of Oncology, Second Affiliated Hospital, Nanjing Medical University, Nanjing, 210000 Jiangsu People’s Republic of China
- The Second Clinical Medical College of Nanjing Medical University, Nanjing, China
| | - Shufen Xu
- Department of Oncology, Second Affiliated Hospital, Nanjing Medical University, Nanjing, 210000 Jiangsu People’s Republic of China
- The Second Clinical Medical College of Nanjing Medical University, Nanjing, China
| | - Peng Peng
- Department of Oncology, Second Affiliated Hospital, Nanjing Medical University, Nanjing, 210000 Jiangsu People’s Republic of China
- The Second Clinical Medical College of Nanjing Medical University, Nanjing, China
| | - Xuezhen Hu
- Jiangsu Provincial Hospital of Traditional Chinese Medicine, Nanjing, China
- Department of Radiology, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, 210000 Jiangsu People’s Republic of China
| | - Keming Wang
- Department of Oncology, Second Affiliated Hospital, Nanjing Medical University, Nanjing, 210000 Jiangsu People’s Republic of China
- The Second Clinical Medical College of Nanjing Medical University, Nanjing, China
| |
Collapse
|
2
|
Yin Q, Tang J, Zhu X. Next-generation sequencing technologies accelerate advances in T-cell therapy for cancer. Brief Funct Genomics 2019; 18:119-128. [PMID: 29982317 DOI: 10.1093/bfgp/ely018] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022] Open
Abstract
Next-generation sequencing has produced a large quantity of DNA or RNA sequences related to the processes occurring within tumors and their microenvironment in a reasonable time and cost. These data have been used to guide the identification of neoantigens and to determine their specific T-cell receptors. Furthermore, adoptive T-cell therapy targeting neoantigens is under development for cancer treatment. In this review, we first provide an overview of sequencing technologies and the updated findings concerning neoantigens related to adoptive T-cell therapy and then summarize the methods and principles underlying the development of next-generation sequencing-based neoantigen-reactive T-cell therapy for cancer.
Collapse
Affiliation(s)
- Qinan Yin
- Clinical Center of National Institutes of Health, Bethesda, MD, USA
| | - Jiaxing Tang
- Shanghai Institute for Advanced Immunochemical Studies (SIAIS), ShanghaiTech University, Shanghai, China
| | - Xuekai Zhu
- Shanghai Institute for Advanced Immunochemical Studies (SIAIS), ShanghaiTech University, Shanghai, China
| |
Collapse
|
3
|
Ji H, Hui B, Wang J, Zhu Y, Tang L, Peng P, Wang T, Wang L, Xu S, Li J, Wang K. Long noncoding RNA MAPKAPK5-AS1 promotes colorectal cancer proliferation by partly silencing p21 expression. Cancer Sci 2019; 110:72-85. [PMID: 30343528 PMCID: PMC6317943 DOI: 10.1111/cas.13838] [Citation(s) in RCA: 30] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/07/2018] [Revised: 09/25/2018] [Accepted: 10/04/2018] [Indexed: 02/06/2023] Open
Abstract
Colorectal cancer (CRC) is the third most common malignancy in the world, and long noncoding RNA (lncRNA) plays a critical role in carcinogenesis. Here, we report a novel lncRNA, MAPKAPK5-AS1, that acts as a critical oncogene in CRC. In addition, we attempted to explore the functions of MAPKAPK5-AS1 on tumor progression in vitro and in vivo. Quantitative RT-PCR was used to examine the expression of MAPKAPK5-AS1 in CRC tissues and cells. Expression of MAPKAPK5-AS1 was significantly upregulated in 50 CRC tissues, and increased expression of MAPKAPK5-AS1 was found to be associated with greater tumor size and advanced pathological stage in CRC patients. Knockdown of MAPKAPK5-AS1 significantly inhibited proliferation and caused apoptosis in CRC cells. We also found that p21 is a target of MAPKAPK5-AS1. In addition, we are the first to report that MAPKAPK5-AS1 plays a carcinogenic role in CRC. MAPKAPK5-AS1 is a novel prognostic biomarker and a potential therapeutic candidate for CRC cancer.
Collapse
Affiliation(s)
- Hao Ji
- Department of OncologySecond Affiliated HospitalNanjing Medical UniversityNanjingChina
- The Second Clinical Medical College of Nanjing Medical UniversityNanjingChina
| | - Bingqing Hui
- Department of OncologySecond Affiliated HospitalNanjing Medical UniversityNanjingChina
- The Second Clinical Medical College of Nanjing Medical UniversityNanjingChina
| | - Jirong Wang
- Department of OncologySecond Affiliated HospitalNanjing Medical UniversityNanjingChina
- The Second Clinical Medical College of Nanjing Medical UniversityNanjingChina
| | - Ya Zhu
- Department of OncologySecond Affiliated HospitalNanjing Medical UniversityNanjingChina
- The Second Clinical Medical College of Nanjing Medical UniversityNanjingChina
| | - Lingyu Tang
- The Second Clinical Medical College of Nanjing Medical UniversityNanjingChina
- Institute of Digestive Endoscopy and Medical Center for Digestive DiseasesSecond Affiliated Hospital of Nanjing Medical UniversityNanjingChina
| | - Peng Peng
- Department of OncologySecond Affiliated HospitalNanjing Medical UniversityNanjingChina
- The Second Clinical Medical College of Nanjing Medical UniversityNanjingChina
| | - Tianjun Wang
- Department of Obstetrics and GynecologyThe First Affiliated Hospital of Nanjing Medical UniversityNanjingChina
| | - Lijuan Wang
- The Second Clinical Medical College of Nanjing Medical UniversityNanjingChina
- Department of GeriatricsSecond Affiliated HospitalNanjing Medical UniversityNanjingChina
| | - Shufeng Xu
- Department of OncologySecond Affiliated HospitalNanjing Medical UniversityNanjingChina
- The Second Clinical Medical College of Nanjing Medical UniversityNanjingChina
| | - Juan Li
- Department of OncologySecond Affiliated HospitalNanjing Medical UniversityNanjingChina
- The Second Clinical Medical College of Nanjing Medical UniversityNanjingChina
| | - Keming Wang
- Department of OncologySecond Affiliated HospitalNanjing Medical UniversityNanjingChina
- The Second Clinical Medical College of Nanjing Medical UniversityNanjingChina
| |
Collapse
|